Literature DB >> 33118916

Comparison of diagnosis and prescribing practices between virtual visits and office visits for adults diagnosed with uncomplicated urinary tract infections within a primary care network.

Kaitlyn L Johnson1, Lisa E Dumkow1, Lisa A Salvati1,2, Kristen M Johnson1, Megan A Yee3, Nnaemeka E Egwuatu4.   

Abstract

OBJECTIVES: Telemedicine visits are an increasingly popular method of care for mild infectious complaints, including uncomplicated urinary tract infections (UTIs), and they are an important target for antimicrobial stewardship programs (ASPs) to evaluate quality of prescribing. In this study, we compared antimicrobial prescribing in a primary care network for uncomplicated UTIs treated through virtual visits and at in-office visits.
DESIGN: Retrospective cohort study comparing guideline-concordant antibiotic prescribing for uncomplicated UTI between virtual visits and office visits.
SETTING: Primary care network composed of 44 outpatient sites and a single virtual visit platform. PATIENTS: Adult female patients diagnosed with a UTI between January 1 and December 31, 2018.
METHODS: Virtual visit prescribing was compared to office visit prescribing, including agent, duration, and patient outcomes. The health system ASP provides annual education to all outpatient providers regarding local antibiogram trends and prescribing guidelines. Guideline-concordant therapy was assessed based on the network's ASP guidelines.
RESULTS: In total, 350 patients were included, with 175 per group. Patients treated for a UTI through a virtual visit were more likely to receive a first-line antibiotic agent (74.9% vs 59.4%; P = .002) and guideline-concordant duration (100% vs 53.1%; P < .001). Patients treated through virtual visits were also less likely to have a urinalysis (0% vs 97.1%; P < .001) or urine culture (0% vs 73.1%; P < .001) ordered and were less likely to revisit within 7 days (5.1% vs 18.9%; P < .001).
CONCLUSIONS: UTI care through a virtual visit was associated with more appropriate antimicrobial prescribing compared to office visits and decreased utilization of diagnostic and follow-up resources.

Entities:  

Year:  2020        PMID: 33118916     DOI: 10.1017/ice.2020.1255

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  The Impact of COVID-19 on Outpatient Antibiotic Prescriptions in Ontario, Canada; An Interrupted Time Series Analysis.

Authors:  Taito Kitano; Kevin A Brown; Nick Daneman; Derek R MacFadden; Bradley J Langford; Valerie Leung; Miranda So; Elizabeth Leung; Lori Burrows; Douglas Manuel; Dawn M E Bowdish; Colleen J Maxwell; Susan E Bronskill; James I Brooks; Kevin L Schwartz
Journal:  Open Forum Infect Dis       Date:  2021-10-30       Impact factor: 3.835

2.  Improving antibiotic use for sinusitis and upper respiratory tract infections: A virtual-visit antibiotic stewardship initiative.

Authors:  Anastasia I Wasylyshyn; Keith S Kaye; Julia Chen; Haley Haddad; Jerod Nagel; Joshua G Petrie; Tejal N Gandhi; Lindsay A Petty
Journal:  Infect Control Hosp Epidemiol       Date:  2022-01-31       Impact factor: 3.254

Review 3.  Opportunities and challenges in improving antimicrobial use during the era of telehealth expansion: A narrative review.

Authors:  Hiroyuki Suzuki; Stephanie C Shealy; Kyle Throneberry; Edward Stenehjem; Daniel Livorsi
Journal:  Antimicrob Steward Healthc Epidemiol       Date:  2021-10-06

4.  Antimicrobial Prescribing in the Telehealth Setting: Framework for stewardship during a period of rapid acceleration within primary care.

Authors:  Kathryn Sine; Haley Appaneal; David Dosa; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2022-07-30       Impact factor: 20.999

5.  Outpatient antibiotic prescribing for common infections via telemedicine versus face-to-face visits: Systematic literature review and meta-analysis.

Authors:  Hiroyuki Suzuki; Alexandre R Marra; Shinya Hasegawa; Daniel J Livorsi; Michihiko Goto; Eli N Perencevich; Michael E Ohl; Jennifer DeBerg; Marin L Schweizer
Journal:  Antimicrob Steward Healthc Epidemiol       Date:  2021-08-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.